Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Core Insights - The Phase 1 APOLLO study of MT-601 in patients with relapsed B cell lymphoma shows a 66% objective response rate in Non-Hodgkin Lymphoma (NHL) patients, with 50% achieving complete response (CR) [1][3] - The study demonstrates a favorable safety profile with no dose limiting toxicities (DLTs) or immune-effector cell associated neurotoxicity syndrome (ICANS) reported [1][8] - The next phase of the study will focus on patients with Diffuse Large B Cell Lymphoma (DLBCL) who have relapsed after or are ineligible for CAR-T cell therapy [1][10] Efficacy and Duration of Response - A total of 24 B-cell lymphoma patients have been treated, with 15 NHL and 9 Hodgkin Lymphoma (HL) patients showing objective responses [4] - Among 12 NHL patients, 8 achieved objective responses (66%), with 6 demonstrating CR (50%) and durable responses lasting from 3 to 24 months [6] - In HL patients, 7 out of 9 had objective responses (78%), with 1 patient achieving CR (11%) [7] Safety Profile - The study tested doses from 100x10 to 400x10 cells, with no DLTs reported at the highest dose [8] - Infusion of MT-601 was well tolerated, with only two Grade 1 cytokine release syndrome (CRS) events reported [8][9] - No serious adverse events were observed, reinforcing the safety of MT-601 [9] Study Design and Future Directions - The APOLLO study includes a dose escalation phase followed by a dose expansion phase, with the maximum dose of 400x10 cells cleared for further investigation [10] - The upcoming dose expansion will enroll patients with DLBCL who have relapsed after anti-CD19 CAR-T cells or are ineligible for such therapy [10] - The company anticipates providing another data update in the first half of 2026 [11] Company Overview - Marker Therapeutics, Inc. is focused on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [2][16] - The lead product, MT-601, is a multi-antigen recognizing (MAR) T cell product targeting six tumor antigens upregulated in lymphoma cells [13] - The company aims to improve patient outcomes through innovative T cell therapies while maintaining operational excellence and financial resource preservation [17]